Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus.

By S. Aşçıoğlu, J. Rex, B. Pauw, J. Bennett, J. Billé, F. Crokaert, D. Denning, J. Donnelly, J. Edwards, Z. Erjavec and 10 more. Clinical Infectious Diseases, 2002

2,437 citations recorded by the source corpus.

Subfields: Epidemiology, Infectious Diseases, Oncology

View Paper: https://www.semanticscholar.org/paper/a1b1cba937bef4c0730189b49cd606dd6af770e1

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Epidemiology

In Infectious Diseases

In Oncology

Citations in the corpus

Multicenter clinical evaluation of the (1-->3) beta-D-glucan assay as an aid to diagnosis of fungal infections in humans. (2005, methodology): “Subjects. Subjects without IFI and subjects with proven or probable IFI (determined according to the European Organization for the Research and Treatment of Cancer/Mycoses Study Group [EORTC/MSG] criteria [ 15 ]) from 6 clinical sites in the United States consented to participate in this study, and ”
Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases. (2006, methodology): “n p 1 A team of experts was convened to review each returned questionnaire and to evaluate certainty of infection using established European Organization for the Research and Treatment of Cancer/Mycoses Study Group criteria, using methods that have been described previously [4, 16].”
Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. (2004, background): “Allergy and Infectious Diseases Mycoses Study Group [12].”
Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. (2002, methodology): “... results of histopathologic tests were considered to have “proven disease.” Patients with clinical signs and symptoms and a BAL specimen that yielded growth on culture or that had positive histopathologic test results were considered to have “probable disease.” Patients with3 clinical signs or sy”
Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. (2008, methodology): “IFIs were classified as either proven, probable, or possible according to definitions of the Invasive Fungal Infection Group of the European Organization for Research and Treatment of Cancer and Mycoses Study Group of the National Institute of Allergy and Infectious Diseases [23].”
Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial). (2007, methodology): “Patients with a diagnosis of possible invasive mold infection, as determined using the EORTC/MSG criteria (i.e., a host factor plus either a clinical or microbiological criterion), were allowed to enroll in the study and to begin treatment with the randomized study drug.”
Histopathologic Diagnosis of Fungal Infections in the 21st Century (2011, background): “An international consensus defining proven, probable, and possible invasive fungal infections for research purposes was published in 2002 and revised in 2008 (7, 43).”
Emergence of Azole Resistance in Aspergillus fumigatus and Spread of a Single Resistance Mechanism (2008, neutral): “Invasive aspergillosis was classified accord ing to the E u ropean O rgan iza tion fo r R esearch and T rea tm en t o f C ancer and Mycoses Study G roup (EORTC)/ MSG consensus defin itions [19].”
Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. (2008, methodology): “1086/588660 zation for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group (EORTC) and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (MSG) published standard definitions for invasive fungal infections for clinical and epidemiological research”
A bedside scoring system (“Candida score”) for early antifungal treatment in nonneutropenic critically ill patients with Candida colonization* (2006, background): “The proposed definitions of “probable,” “possible,” and “proven” opportunistic fungal infections intended for immunocompromised patients (20) may be unreliable for nonneutropenic patients (21).”
Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. (2007, methodology): “Patients were enrolled to receive posaconazole for salvage treatment if the investigator confirmed a diagnosis of invasive aspergillosis, in accordance with the European Organization for Research and Treatment–Mycoses Study Group (EORTC-MSG) criteria [18], and if they were refractory to at least 7 d”
Epidemiology and outcomes of candidemia in 2019 patients: data from the prospective antifungal therapy alliance registry. (2009, methodology): “A diagnosis of candidemia was made on the basis of 1 blood cultures growing Candida species and the presence of relevant clinical signs and symptoms, as enumerated in the guidelines of the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the”